600637.SS Oriental Pearl Group Co.,Ltd.

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the agreement, NAMSA will take ownership of WuXi’s facilities in Minnesota and Georgia.

Shares of WuXi group companies jumped Monday after U.S. President-elect Trump promised to save TikTok and held a call with his counterpart in China, sparking tentative hopes that some areas of U.S ...

Legislation would have cut Chinese businesses off from US WuXi executives say the companies continue to sign new clients WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Plus, news about Neur­i­zon: WuXi AppTec di­vests again: The com­pa­ny is sell­ing its US med­ical de­vice test­ing op­er­a­tions, in­clud­ing fa­cil­i­ties in Min­neso­ta and ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...